Company profile

Alto Neuroscience company profile

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
00051-00100 employees
Revenue range
$10K+
Founded
2019-01-01

Headquarters

Headquarters
Medford, Wisconsin, United States
Postal code
94022
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Ipo
Funding rounds
12
Total equity funding
$254.3M
Last funding
Post Ipo Equity / $50M / 2025-10-20
Last equity funding
Post Ipo Equity / $50M
Investors
34
Lead investors
9
Founders
3
Articles
360
Exited on
2024-02-02

Founders and investors

Founders

Amit EtkinDan SegalWei Wu

Lead investors

Alkeon CapitalAlpha Wave VenturesApeiron Investment GroupInVivium CapitalK2 HealthVenturesLightswitch CapitalPerceptive AdvisorsTim KendallWellcome Trust

Investors

Eli LillyFranklin TempletonGaingelsValor Equity PartnersVivo Capital

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.